This study looks at how a medicine called mavacamten affects the heart's muscle in adults with a heart problem called obstructive hypertrophic cardiomyopathy (oHCM). oHCM means the heart muscle is too thick, making it hard for blood to leave the heart.
To be part of the study, you must have oHCM, with a heart condition class II or III by the New York Heart Association (NYHA). Your heart's blood flow, called the left ventricular outflow tract (LVOT), must be blocked by at least 30 millimeters of mercury (mmHg) and even more after exercise. Your heart should also pump well, with a left ventricular ejection fraction (LVEF) of 55% or higher.
If you have other heart problems, like coronary artery disease, had a heart attack, or have a pacemaker, you cannot join. The study uses cardiac magnetic resonance imaging (CMR) to see changes in the heart.
- This study requires several visits for imaging tests.
- Participants should be comfortable with MRI scans.
- Discuss any heart devices with your doctor before joining.